Menu Back toSession-7-Orphan-Medicines-Doing-Studies-in-Small-Populations

Better Medicines for Children, A DIA/EFGCP Conference

Plan ahead and join us to reflect on the importance of two major headways that are currently affecting Paediatric research: Innovative approaches to Drug Development and impact of the current environment on the Regulatory and Research Infrastructure


Session 7: Orphan Medicines – Doing Studies in Small Populations

Session Chair(s)

Geneviève  Le Visage, PharmD, MSc

Geneviève Le Visage, PharmD, MSc

  • Regional Head RA Europe Policy & Liaison
  • Novartis Pharma AG, Switzerland
  Session Chair

Session Chair

  • France
Session 7: Orphan Medicines – Doing Studies in Small Populations

Speaker(s)

Fabio  D’Atri

Feedback on the Joint Review of the Paediatric and Orphan Regulations

Fabio D’Atri

  • Policy Officer, Deputy Head of Unit
  • Unit B5 Directorate General for Health and Food Safey, European Commission , Belgium
Thomas  Kühler, PhD, MSc

Orphan Medicines for Paediatric Use - A focus on the European Union

Thomas Kühler, PhD, MSc

  • Head GRSP EU/AMEE
  • Sanofi R&D, France

Contact us


Registration Questions?

Send Email
+41 61 225 51 51